During the corresponding time, Recursion Pharmaceuticals Inc saw a revenue deteriorated by -60.1 % year on year, sequentially revenue grew by 18.51 %. While revenue at the Recursion Pharmaceuticals Inc 's corporate clients
:Recursion Pharmaceuticals, a clinical-stage technology-driven drug discovery company, announced key advancements in its drug development pipeline and corporate partnerships. Notably, the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for REC-1245, a potential first-in-class RBM39 degrader aimed at treating biomarker-enriched solid tumors and lymphoma. Simultaneously, Recursion has entered into a definitive agreement with Exscientia to enhance drug discovery efficiencies, anticipated to generate annual synergies of approximately $100 million. Additionally, research findings published in Nature Genetics underscore the company s capabilities in genomic studie...
Recursion Pharmaceuticals Raises $200 Million in Public Offering to Advance Drug Discovery TechnologySalt Lake City-based TechBio company, Recursion Pharmaceuticals, Inc. (Recursion), recently announced the pricing of its underwritten public offering of Class A common stock. The company aims to raise approximately $200 million through the sale of 30,769,230 shares, priced at $6.50 per share. Recursion has also provided the underwriters a 30-day option to purchase an additional 4,615,384 shares.Recursion Pharmaceuticals has gained prominence in the clinical stage through its innovative approach to drug discovery. By leveraging cutting-edge technology and decoding complex biological data, the company aims to i...
In a strategic move to further establish its dominance in the field of TechBio, Recursion Pharmaceuticals has announced plans to open a new office in London s vibrant Kings Cross neighborhood. Alongside this exciting development, the company has appointed renowned scientist, Michael Bronstein, as their Scientific Advisor and is embarking on an extensive recruitment effort to fill 20 open positions in technology and biology. This pioneering move not only solidifies Recursion s commitment to innovation but also sets the stage for the company to attract world-class talent in the rapidly evolving field.Recursion Pharmaceuticals, an industry leader in TechBio, is set to expand its global footprint with the openin...
Recursion Unveils Groundbreaking Drug Discovery Software at J.P. Morgan Healthcare ConferenceAt the highly anticipated J.P. Morgan Healthcare Conference, Recursion made waves by introducing its innovative LOWE software. The company, renowned for its cutting-edge approach to drug discovery, showcased live demonstrations of LOWE and raised eyebrows with its impressive capabilities. LOWE, a new LLM-based software, is poised to revolutionize the field of drug discovery. It can tackle complex tasks with ease and seamlessly coordinate both wet-lab and dry-lab components of the Recursion OS. What sets LOWE apart is its ability to understand and respond to natural language commands, making it a game-changer for scie...
Sources:
Recursion Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Recursion Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Recursion Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
177.38 %